{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:41:34Z","timestamp":1772754094483,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1007\/s11914-004-0010-6","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T22:47:20Z","timestamp":1180133240000},"page":"17-23","source":"Crossref","is-referenced-by-count":12,"title":["Rational use of oral bisphosphonates for the treatment of osteoporosis"],"prefix":"10.1007","volume":"2","author":[{"given":"Julian M. R.","family":"Mathoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Cranney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10_CR1","first-page":"921","volume":"155","author":"DA Hanley","year":"1996","unstructured":"Hanley DA, Josse RG: Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. CMAJ 1996, 155:921\u2013923.","journal-title":"CMAJ"},{"key":"10_CR2","volume-title":"The State of Osteoporosis and Low Bone Mass in Our Nation","author":"America\u2019s Bone Health","year":"2002","unstructured":"America\u2019s Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. Washington, DC: National Osteoporosis Foundation; 2002."},{"key":"10_CR3","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/archinte.1996.00440130053006","volume":"156","author":"WS Browner","year":"1996","unstructured":"Browner WS, Pressman AR, Nevitt MC, et al.:Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 1996, 156:1521\u20131525.","journal-title":"Arch Intern Med"},{"key":"10_CR4","doi-asserted-by":"crossref","unstructured":"Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis: Am J Med 1993, 94:646\u2013650.","DOI":"10.1016\/0002-9343(93)90218-E"},{"key":"10_CR5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-137-6-200209170-00015","volume":"137","author":"HD Nelson","year":"2002","unstructured":"Nelson HD, Helfand M, Woolf SH, et al.:Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 137:529\u2013541.","journal-title":"Ann Intern Med"},{"key":"10_CR6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994, 4:368\u2013381.","journal-title":"Osteoporos Int"},{"key":"10_CR7","unstructured":"Physician\u2019s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 1998."},{"key":"10_CR8","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1210\/jcem.84.6.5710","volume":"84","author":"PD Miller","year":"1999","unstructured":"Miller PD, Zapalowski C, Kulak CA, et al.:Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab 1999, 84:1867\u20131871.","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR9","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1001\/jama.288.15.1898","volume":"288","author":"DW Bates","year":"2002","unstructured":"Bates DW, Black DM, Cummings SR: Clinical use of bone densitometry: clinical applications. JAMA 2002, 288:1898\u20131900.","journal-title":"JAMA"},{"key":"10_CR10","first-page":"S1","volume":"167","author":"JP Brown","year":"2002","unstructured":"Brown JP, Josse RG: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002, 167:S1-S34.","journal-title":"CMAJ"},{"key":"10_CR11","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","volume":"97","author":"GA Rodan","year":"1996","unstructured":"Rodan GA, Fleisch HA: Bisphosphonates: mechanisms of action. J Clin Invest 1996, 97:2692\u20132696.","journal-title":"J Clin Invest"},{"key":"10_CR12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","volume":"13","author":"SP Luckman","year":"1998","unstructured":"Luckman SP, Hughes DE, Coxon FP, et al.:Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581\u2013589.","journal-title":"J Bone Miner Res"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, et al.:Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604\u2013610.","journal-title":"N Engl J Med"},{"key":"10_CR14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","volume":"323","author":"NB Watts","year":"1990","unstructured":"Watts NB, Harris ST, Genant HK, et al.:Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990, 323:73\u201379.","journal-title":"N Engl J Med"},{"key":"10_CR15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","volume":"322","author":"T Storm","year":"1990","unstructured":"Storm T, Thamsborg G, Steiniche T, et al.:Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990, 322:1265\u20131271.","journal-title":"N Engl J Med"},{"key":"10_CR16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/rheumatology\/37.1.87","volume":"37","author":"TP Staa van","year":"1998","unstructured":"van Staa TP, Abenhaim L, Cooper C: Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol 1998, 37:87\u201394.","journal-title":"Br J Rheumatol"},{"key":"10_CR17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s001980170147","volume":"12","author":"A Cranney","year":"2001","unstructured":"Cranney A, Guyatt G, Krolicki N, et al.:A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001, 12:140\u2013151. This is a widely cited meta-analysis of etidronate therapy in postmenopausal osteoporosis.","journal-title":"Osteoporos Int"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/j.1875-9114.1998.tb03899.x","volume":"18","author":"DL Lourwood","year":"1998","unstructured":"Lourwood DL: The pharmacology and therapeutic utility of bisphosphonates. Pharmacotherapy 1998, 18:779\u2013789.","journal-title":"Pharmacotherapy"},{"key":"10_CR19","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, et al.:Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000, 85:4118\u20134124.","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR20","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al.:Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535\u20131541.","journal-title":"Lancet"},{"key":"10_CR21","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, et al.:Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077\u20132082.","journal-title":"JAMA"},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Wells G, Willan A, et al.:Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002, 23:508\u2013516. A widely cited meta-analysis of alendronate therapy in postmenopausal osteoporosis.","journal-title":"Endocr Rev"},{"key":"10_CR23","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1210\/jcem.86.11.7988","volume":"86","author":"JD Ringe","year":"2001","unstructured":"Ringe JD, Faber H, Dorst A: Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001, 86:5252\u20135255.","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR24","unstructured":"Actonel (risedronate) [package insert]. Cincinnati, OH: Proctor & Gamble Pharmaceuticals; 2000."},{"key":"10_CR25","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, et al.:Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344\u20131352.","journal-title":"JAMA"},{"key":"10_CR26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, et al.:Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83\u201391.","journal-title":"Osteoporos Int"},{"key":"10_CR27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8529(02)00024-5","volume":"31","author":"GH Guyatt","year":"2002","unstructured":"Guyatt GH, Cranney A, Griffith L, et al.:Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 2002, 31:659\u2013679.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10_CR28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, et al.:Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333\u2013340.","journal-title":"N Engl J Med"},{"key":"10_CR29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Tugwell P, Adachi J, et al.:Meta-analyses of therapies for postmenopausal osteoporosis. III. Metaanalysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:517\u2013523. This is a widely cited meta-analysis of risedronate therapy in postmenopausal osteoporosis.","journal-title":"Endocr Rev"},{"key":"10_CR30","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00002018-200225110-00003","volume":"25","author":"RB Kherani","year":"2002","unstructured":"Kherani RB, Papaioannou A, Adachi JD: Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review. Drug Saf 2002, 25:781\u2013790.","journal-title":"Drug Saf"},{"key":"10_CR31","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1111\/j.1572-0241.2000.03258.x","volume":"95","author":"F Lanza","year":"2000","unstructured":"Lanza F, Schwartz H, Sahba B, et al.:An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000, 95:3112\u20133117.","journal-title":"Am J Gastroenterol"},{"key":"10_CR32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","volume":"160","author":"DC Bauer","year":"2000","unstructured":"Bauer DC, Black D, Ensrud K, et al.:Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000, 160:517\u2013525.","journal-title":"Arch Intern Med"},{"key":"10_CR33","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","volume":"77","author":"H Taggart","year":"2002","unstructured":"Taggart H, Bolognese MA, Lindsay R, et al.:Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002, 77:262\u2013270.","journal-title":"Mayo Clin Proc"},{"key":"10_CR34","first-page":"1","volume":"12","author":"T Schnitzer","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G, et al.:Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000, 12:1\u201312.","journal-title":"Aging (Milano)"},{"key":"10_CR35","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","volume":"17","author":"SL Greenspan","year":"2002","unstructured":"Greenspan SL, Bone G, III, Schnitzer TJ, et al.:Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002, 17:1988\u20131996.","journal-title":"J Bone Miner Res"},{"key":"10_CR36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","volume":"71","author":"JP Brown","year":"2002","unstructured":"Brown JP, Kendler DL, McClung MR, et al.:The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103\u2013111.","journal-title":"Calcif Tissue Int"},{"key":"10_CR37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s001980200000","volume":"13","author":"CH Turner","year":"2002","unstructured":"Turner CH: Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002, 13:97\u2013104.","journal-title":"Osteoporos Int"},{"key":"10_CR38","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0002-9343(97)00278-7","volume":"103","author":"PD Miller","year":"1997","unstructured":"Miller PD, Watts NB, Licata AA, et al.:Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997, 103:468\u2013476.","journal-title":"Am J Med"},{"key":"10_CR39","unstructured":"Emkey RD, Reid I, Mulloy A, et al.: Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women. Phase III Osteoporosis Treatment Study Group. Paper presented at the ASBMR 24th Annual Meeting. San Antonio, TX, 2002."},{"key":"10_CR40","first-page":"3109","volume":"85","author":"RP Tonino","year":"2000","unstructured":"Tonino RP, Meunier PJ, Emkey R, et al.:Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000, 85:3109\u20133115.","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6290","volume":"6","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Brazier JE, Stevenson M, et al.:Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002, 6:1\u2013146.","journal-title":"Health Technol Assess"},{"key":"10_CR42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00019053-200321050-00002","volume":"21","author":"O Johnell","year":"2003","unstructured":"Johnell O, Jonsson B, Jonsson L, Black D: Cost effectiveness of alendronate (Fosamax\u00ae) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003, 21:305\u2013314.","journal-title":"Pharmacoeconomics"},{"key":"10_CR43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/qjmed\/95.5.305","volume":"95","author":"CP Iglesias","year":"2002","unstructured":"Iglesias CP, Torgerson DJ, Bearne A, Bose U: The cost utility of bisphosphonate treatment in established osteoporosis. QJM 2002, 95:305\u2013311.","journal-title":"QJM"},{"key":"10_CR44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W","volume":"6","author":"MJ Buxton","year":"1997","unstructured":"Buxton MJ, Drummond MF, Van Hout BA, et al.:Modeling in economic evaluation: an unavoidable fact of life. Health Econ 1997, 6:217\u2013227.","journal-title":"Health Econ"},{"key":"10_CR45","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"MF Drummond","year":"1997","unstructured":"Drummond MF, O\u2019Brien B, Stoddart GL, et al.: Methods for the Economic Evaluation of Health Care Programmes, edn 2. Toronto: Oxford University Press; 1997.","edition":"edn 2"},{"key":"10_CR46","first-page":"448","volume":"27","author":"DT Grima","year":"2002","unstructured":"Grima DT, Burge RT, Becker DL, Tosteson ANA: Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. Pharm Ther 2002, 27:448\u2013455.","journal-title":"Pharm Ther"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-004-0010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-004-0010-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-004-0010-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T15:12:21Z","timestamp":1707923541000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-004-0010-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s11914-004-0010-6","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}